ECST : European Committee for Standardization of Clinical Trials with Psychotropics. Strasbourg FRA, 1994/05/26.
This paper considers some of the theoretical and practical problems of conducting cost-utility analyses alongside clinical trials.
In order to measure utilities of different health states in a clinical trial a number of critical assumptions have to be made.
Some of these assumptions are questionable on a theoretical level, others empirically invalid.
The practical problems of measuring utilities are discussed.
The standard gamble is shown to be the most validated method of utility measurement, but still based on very strong assumptions.
The standard gamble instrument is also costly and difficult to administer in clinical trials.
Other instruments are found to be less valid than the standard gamble.
It is concluded that although cost-utility analysis seems relevant in some instances, investigators should avoid this assessment of utility and instead measure cost-effectiveness, cost-benefit and quality of life.
Mots-clés Pascal : Economie santé, Traitement, Chimiothérapie, Psychotrope, Trouble psychiatrique, Essai clinique, Homme, Analyse coût utilité
Mots-clés Pascal anglais : Health economy, Treatment, Chemotherapy, Psychotropic, Mental disorder, Clinical trial, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0309045
Code Inist : 002B02B11. Création : 10/04/1997.